» Articles » PMID: 7886394

Omeprazole Plus Amoxicillin for Cure of Helicobacter Pylori Infection. Factors Influencing the Treatment Success

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 1994 Dec 1
PMID 7886394
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Omeprazole plus amoxicillin may cure Helicobacter pylori infection. However, the published results vary rather widely, and the factors influencing the treatment success remain unclear.

Methods: Four hundred and twenty-three H. pylori-positive patients were treated with 1- or 2-week regimens comprising 40 mg or 80 mg omeprazole and amoxicillin in 11 prospective protocols. A complete set of data was available for 405 patients (ulcer disease, n = 383; dyspepsia, n = 22) and was submitted to uni- and multi-variate statistical analyses to elucidate the factors affecting the cure rates of the infection; 18 patients were lost to follow-up.

Results: The overall proportion of H. pylori cure was 76%. Insufficient compliance (p < 0.001), a short duration of treatment (p < 0.001), smoking (p = 0.003), and omeprazole pretreatment (p = 0.041) were the significant independent factors predicting treatment failure, whereas advanced age (p = 0.002), high scores of grade and of activity of gastritis (p = 0.035 and p = 0.019, respectively), and gastric ulcer disease (p = 0.058) were independent factors predicting treatment success.

Conclusions: Several patient- and therapy-related factors diminish or increase the rate of H. pylori cure obtained by omeprazole/amoxicillin. These should be considered in future studies comparing different treatment regimens for curing H. pylori infection and also when designing treatment regimens applicable for routine clinical practice.

Citing Articles

Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations.

Yu J, Lv Y, Yang P, Jiang Y, Qin X, Wang X BMC Gastroenterol. 2023; 23(1):365.

PMID: 37880587 PMC: 10599016. DOI: 10.1186/s12876-023-03002-z.


Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study.

Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y Helicobacter. 2020; 25(5):e12717.

PMID: 32548932 PMC: 7540066. DOI: 10.1111/hel.12717.


eradication in patients with type 2 diabetes mellitus: Multicenter prospective observational study.

Nam S, Park S, Lee S, Choi D, Lee S, Bang C SAGE Open Med. 2019; 7:2050312119832093.

PMID: 30815260 PMC: 6383094. DOI: 10.1177/2050312119832093.


Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?.

Graham D, Lu H, Shiotani A Saudi J Gastroenterol. 2017; 23(5):265-267.

PMID: 28937019 PMC: 5625361. DOI: 10.4103/sjg.SJG_292_17.


Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial.

Lee C, Shih H, Yu M, Lee M, Chang Y, Lai Y Chin J Integr Med. 2016; 23(3):176-182.

PMID: 27761791 DOI: 10.1007/s11655-016-2531-0.